诺和诺德公司宣布，其备受关注的减肥药物Wegovy订阅服务将从3月31日起正式上线。该计划将通过数字健康平台Ro、体重管理服务商WeightWatchers以及远程医疗提供商LifeMD向用户开放。
这一举措标志着诺和诺德在拓宽Wegovy可及性方面迈出重要一步。通过与合作方联手，患者将能更便捷地获得这款GLP-1受体激动剂药物的专业指导和支持服务。
订阅计划的推出正值减肥药物市场需求激增之际。分析认为，这种创新服务模式有望帮助更多肥胖症患者获得规范治疗，同时强化诺和诺德在代谢疾病领域的市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.